Recent studies show rapamycin extends lifespan in animals comparably to dietary restriction like intermittent fasting, but human data remains limited with both offering mTOR inhibition benefits. No clear winner emerges yet—rapamycin may edge out in late-life starts, while fasting proves more accessible. This post dives into mechanisms, trials, and real-world insights to help you weigh…

Rapamycin shows promise in slowing or partially reversing epigenetic clocks in preclinical models like human skin cells and mice, however human clinical evidence remains limited and mixed. Experts like Matt Kaeberlein highlight ongoing dog trials as key tests for translation, while users report variable biomarker shifts alongside side effects. This post dives into mechanisms, data,…

The quest to slow biological time is no longer fringe science; it's a multi-billion dollar industry. Walking into a pharmacy or scrolling online presents a dizzying array of pills and powders claiming to extend healthspan. But when you strip away the marketing, the question remains: What are the best longevity supplements actually supported by clinical data? While…

The search for Rapamycin capsules formulated for longevity has moved from fringe biohacking forums to mainstream medical consultations. Following the release of the PEARL trial results in 2025 and new data on DNA damage protection in early 2026, demand has surged. However, sourcing remains complex. Unlike over-the-counter supplements, rapamycin (sirolimus) is a prescription drug, and the formulation…

In 2026, the discussion around longevity has moved from "What is the best pill?" to "How do we balance the pathways?" The debate over Rapamycin vs. Metformin for longevity has reached a turning point in 2026. While both molecules dominated early geroscience discussions, recent meta-analyses and clinical data now distinguish between "fringe benefits" and "fundamental…

For many in the longevity community, the six-month mark is the "Gold Standard" milestone. It is the point where the initial placebo effects fade, and the real biological data—from lipid panels to biological age clocks—begins to tell a definitive story. While clinical trials like the ERAP trial for Alzheimer’s and the Kraig et al. study…

Rapamycin and Metabolic Effects: Blood Sugar, Cholesterol, and What to Monitor The pursuit of human longevity has transitioned from speculative "elixirs" to the rigorous science of geroprotection, with the mechanistic target of rapamycin (mTOR) pathway serving as a central hub. While Rapamycin is the most robust pharmacological intervention for extending lifespan in model organisms, its…

Navigating the landscape of geroprotectors requires a shift from traditional disease treatment to proactive biological optimization. Rapamycin dosing for longevity has moved beyond theoretical mouse models and into the clinics of specialty practitioners, yet the transition from a daily transplant drug to an intermittent anti-aging protocol requires precision to maximize autophagy while avoiding metabolic pitfalls.…

For decades, the search for a true "longevity pill" was considered more science fiction than science. However, the discovery of the mTOR pathway and its inhibition by a soil-derived molecule called rapamycin has shifted that perspective. While animal studies have long shown that rapamycin can extend lifespan by up to 60%, the question of whether…

“New research suggests low-dose rapamycin may reduce DNA damage in aging immune cells, supporting healthier aging and potentially extending human healthspan.” Recent findings suggest that rapamycin, an mTOR-inhibiting compound with established geroprotective effects in animal models, may enhance DNA damage resilience in aging human immune cells. This mechanism provides a compelling biologic rationale for its…